Canaccord analyst Caitlin Cronin raised the firm’s price target on Smith & Nephew to $28 from $27 and keeps a Hold rating on the shares. The firm said they delivered a solid Q1 overall, slightly beating consensus and maintaining its guidance through the P&L. The company saw similar LSD reported growth across its portfolio segments as China headwinds which it believes have peaked, and one fewer selling day impacted growth as anticipated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Cautious Hold Rating on Smith & Nephew Amid Mixed Performance and Ambitious Targets
- Smith & Nephew Announces Successful AGM Resolutions
- Smith & Nephew Reports Strong Q1 2025 Growth Amid Challenges
- Smith & Nephew Reports Strong Start to 2025 with Revenue Growth
- Nuo Therapeutics enters Centrio distribution pact with Smith & Nephew